The Role of Public-Private Partnerships in the Cancer Moonshot: How PACT can Transform Cancer Immunotherapy Clinical Trials
By David Wholley, M.Phil, Senior Vice President of Research Partnerships at the Foundation for the National Institutes of Health (FNIH).
June 15, 2018 — Today, the Moderate Alcohol and Cardiovascular Health Trial (MACH) Working Group presented a report to the National Institutes of Health (NIH) Advisory Committee to the Director. The following is the FNIH’s response to the report.
June 12, 2018 — The Foundation for the National Institutes of Health (FNIH) has received top honors again this year from Charity Navigator by earning its coveted 4-star rating. The nation’s largest charity evaluator has recognized the FNIH with its highest rating for demonstrating strong financial health and commitment to accountability and transparency. Only 13 percent of the charities evaluated by Charity Navigator have received at least four consecutive, 4-stars, indicating the FNIH “outperforms most charities in America.”
American Journal of Tropical Medicine and Hygiene Publishes Recommendations for Safe and Ethical Testing of Gene Drive Mosquitoes to Reduce Malaria Transmission in Africa
June 7, 2018 — The American Journal of Tropical Medicine and Hygiene (AJTMH) has published an article outlining recommendations for the safe and ethical testing of gene drive technology on mosquitoes to reduce the burden of malaria transmission in Africa.
The FNIH Biomarkers Consortium Launches Project to Improve Diagnosis and Treatment of Neurodegenerative and Psychiatric Diseases
April 26, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a project, under its Neuroscience Steering Committee, with the potential to improve diagnosis and the development of targeted therapies for Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD). Research continues to strengthen the connection between inflammatory processes in the brain with the development and progression of multiple central nervous system (CNS) disorders, including AD and MDD.
December 7, 2017 — Science Translational Medicine has published an article by experts from the Foundation for the National Institutes of Health, the National Institutes of Health, the U.S. Food and Drug Administration (FDA), industry, academia and not-for-profit organizations that outlines a framework for the level of evidence needed to support qualification of biological markers (biomarkers) for use in drug development decision making.